Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fractyl Health, Inc. ( (GUTS) ) has provided an update.
On August 29, 2025, Fractyl Health, Inc. announced the appointment of Christopher Thompson, M.D. as a Class I director and Ian Sheffield as a Class II director, effective September 2, 2025. Dr. Thompson’s term will expire at the 2028 annual meeting, while Mr. Sheffield’s term will end at the 2026 meeting. Mr. Sheffield will also join the audit committee. Both directors will participate in the Non-Employee Director Compensation Program, receiving annual retainers and initial equity awards. Additionally, Amy W. Schulman resigned as a Class I director and from the Nominating and Corporate Governance Committee, effective September 2, 2025, without any disputes with the company.
The most recent analyst rating on (GUTS) stock is a Buy with a $3.60 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative cash flows. While recent corporate events and earnings call insights provide some optimism, the company’s financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Average Trading Volume: 866,660
Technical Sentiment Signal: Sell
Current Market Cap: $70.11M
See more data about GUTS stock on TipRanks’ Stock Analysis page.